Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

Matthew T Seymour; Lindsay C Thompson; Harpreet S Wasan; Gary Middleton; Alison E Brewster; Stephen F Shepherd; M Sinead O'Mahony; Timothy S Maughan; Mahesh Parmar; Ruth E Langley; FOCUS2 Investigators

doi:10.1016/S0140-6736(11)60399-1

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

Matthew T Seymour, Lindsay C Thompson, Harpreet S Wasan, Gary Middleton, Alison E Brewster, Stephen F Shepherd, M Sinead O'Mahony, Timothy S Maughan, Mahesh Parmar, Ruth E Langley, FOCUS2 Investigators

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

260 Citations (Scopus)

Abstract

Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.

Original language	English
Pages (from-to)	1749-59
Number of pages	11
Journal	Lancet
Volume	377
Issue number	9779
DOIs	https://doi.org/10.1016/S0140-6736(11)60399-1
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(11)60399-1

Cite this

Seymour, M. T., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., O'Mahony, M. S., Maughan, T. S., Parmar, M., Langley, R. E., & FOCUS2 Investigators (2011). Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, 377(9779), 1749-59. https://doi.org/10.1016/S0140-6736(11)60399-1

@article{72a50793271f40baa4ba07c038220680,

title = "Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial",

abstract = "Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.",

author = "Seymour, {Matthew T} and Thompson, {Lindsay C} and Wasan, {Harpreet S} and Gary Middleton and Brewster, {Alison E} and Shepherd, {Stephen F} and O'Mahony, {M Sinead} and Maughan, {Timothy S} and Mahesh Parmar and Langley, {Ruth E} and {FOCUS2 Investigators}",

year = "2011",

doi = "10.1016/S0140-6736(11)60399-1",

language = "English",

volume = "377",

pages = "1749--59",

journal = "Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9779",

}

Seymour, MT, Thompson, LC, Wasan, HS, Middleton, G, Brewster, AE, Shepherd, SF, O'Mahony, MS, Maughan, TS, Parmar, M, Langley, RE & FOCUS2 Investigators 2011, 'Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial', Lancet, vol. 377, no. 9779, pp. 1749-59. https://doi.org/10.1016/S0140-6736(11)60399-1

TY - JOUR

T1 - Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2)

T2 - an open-label, randomised factorial trial

AU - Seymour, Matthew T

AU - Thompson, Lindsay C

AU - Wasan, Harpreet S

AU - Middleton, Gary

AU - Brewster, Alison E

AU - Shepherd, Stephen F

AU - O'Mahony, M Sinead

AU - Maughan, Timothy S

AU - Parmar, Mahesh

AU - Langley, Ruth E

AU - FOCUS2 Investigators

PY - 2011

Y1 - 2011

N2 - Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.

AB - Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer.

U2 - 10.1016/S0140-6736(11)60399-1

DO - 10.1016/S0140-6736(11)60399-1

M3 - Article

C2 - 21570111

SN - 1474-547X

VL - 377

SP - 1749

EP - 1759

JO - Lancet

JF - Lancet

IS - 9779

ER -

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this